What are the requirements of the declaration of Helsinki?

What are the requirements of the declaration of Helsinki?

Physician scientists must also take into account their local ethical, legal, and regulatory norms and standards for research involving human subjects. These requirements should not diminish the protections set forth in the Declaration of Helsinki, but additional protections may be afforded.

Is the declaration of Helsinki about medical experimentation?

This article is about the human medical experimentation ethics document. For other uses, see Declaration of Helsinki (disambiguation).

When was the second revision of the declaration of Helsinki?

Subsequent revisions between 1975 and 2000 were relatively minor, so the 1975 version was effectively that which governed research over a quarter of a century of relative stability. The second revision (1983) included seeking the consent of minors where possible.

When was the declaration of Helsinki adopted by the WMA?

Declaration of Helsinki. The Declaration of Helsinki (DoH) is the World Medical Association’s (WMA) best-known policy statement. The first version was adopted in 1964 and has been amended seven times since, most recently at the General Assembly in October 2013. The current (2013) version is the only official one;

What is the World Medical Association Declaration of Helsinki?

The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data.

The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It must subjects set forth in this Declaration. The committee must have the right to monitor

Why was placebos included in the declaration of Helsinki?

In 1996, the declaration added a reference to placebos in response to concerns about trials in perinatal HIV transmission in developing countries. Critics pointed out that continuing to use placebos when efficacy had been demonstrated implied a different ethical standard for developing countries than for developed ones.